S5068
沙美特罗 羟萘甲酸盐
≥98% (HPLC), β2 adrenoceptor agonist, solid
别名:
(±) 4-羟基-a1-[[[6-(4-苯基丁氧基)己基]氨基]间-乙基]-1,3-苯二甲醇 羟萘甲酸盐, GR 33343X 羟萘甲酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C25H37NO4 · C11H8O3
化学文摘社编号:
分子量:
603.75
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
沙美特罗 羟萘甲酸盐, ≥98% (HPLC), solid
SMILES string
OC(=O)c1ccc2ccccc2c1O.OCc3cc(ccc3O)C(O)CNCCCCCCOCCCCc4ccccc4
InChI key
XTZNCVSCVHTPAI-UHFFFAOYSA-N
InChI
1S/C25H37NO4.C11H8O3/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21;12-10-8-4-2-1-3-7(8)5-6-9(10)11(13)14/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2;1-6,12H,(H,13,14)
assay
≥98% (HPLC)
form
solid
color
white
solubility
H2O: slightly soluble, ethanol: slightly soluble, methanol: freely soluble
originator
GlaxoSmithKline
Quality Level
Gene Information
human ... ADRB2(154)
正在寻找类似产品? 访问 产品对比指南
Application
昔萘酸沙美特罗与人血清白蛋白结合用于研究兔的免疫反应。7
Biochem/physiol Actions
β2-肾上腺素能受体激动剂。
昔萘酸沙美特罗是一种 β2 型肾上腺素受体激动剂，具有更持久的支气管扩张作用和抗炎作用。它可以放松气道平滑肌、稳定肥大细胞并调节组胺的释放。昔萘酸沙美特罗对轻度哮喘、慢性阻塞性肺疾病特别有效。5,6
Features and Benefits
该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Marc Decramer et al.
Respiratory medicine, 107(2), 223-232 (2012-12-12)
Indacaterol is a once-daily, long-acting β(2)-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are
Claus Vogelmeier et al.
Respiratory medicine, 107(1), 75-83 (2012-10-30)
The objective of this study was to investigate the effect of tiotropium compared with salmeterol on exacerbations in patients with moderate (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II) chronic obstructive pulmonary disease (COPD) and those naïve to
Finney, P.A., et al.
British Journal of Pharmacology, 132, 1267-1270 (2001)
K F Chung
International journal of chronic obstructive pulmonary disease, 1(3), 235-242 (2007-12-01)
Clinical trials of a combination therapy of an inhaled corticosteroid, fluticasone propionate (FP), with a long-acting beta2-agonist, salmeterol (Sal), have demonstrated a greater improvement in lung function and in quality of life measures after the combination compared with either component
Robert J Slack et al.
The Journal of pharmacology and experimental therapeutics, 344(1), 218-230 (2012-11-08)
Vilanterol trifenatate (vilanterol) is a novel, long-acting β(2)-adrenoceptor (β(2)-AR) agonist with 24 h activity. In this study, we describe the preclinical pharmacological profile of vilanterol using radioligand binding and cAMP studies in recombinant assays as well as human and guinea
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持